

MERCK AFRICA LUMINARY

Together We Commit To Africa



Darmstadt, Germany 23rd, 24th October

Table of Contents

I. Agenda.....	1-5
II. Speakers Profiles.....	6-35
III. Briefing Document.....	36-42



MERCK AFRICA LUMINARY AGENDA

DAY 1		23 rd October 2014 (Thursday)	Atrium B4
08:00 – 08:15	Welcome and Introduction – Merck Serono Vision for Africa Elcin Ergun		
08:15 – 08:45	Merck Family History Dr. Frank Stangenberg-Haverkamp		
08:45 – 09:15	Merck for Africa Dr. Karl-Ludwig Kley		
09:15 – 09:40	Merck Business and Responsibility Dr. Stefan Oschmann		
09:40 – 10:05	Merck Serono Overview and Vision Belen Garijo		
10:05 – 10:15	Group photo		
10:15 – 11:10	"Together We Commit to Africa" Certify our Commitment to Africa All Guests and Merck Employees		
11:10 – 11:30	COFFEE BREAK		
11:30 – 13:30	R&D Manufacturing Site Scientific Visit		
	(2 Groups) each Group is 50 Guests – 25 Guests in each sub-groups Group A will take the bus for visit and Group B will stay behind at the Atrium for a parallel activity		
11:30 – 13:30	Activity for Group A (Scientific Tour) Group A (50 Guests) does visit (Visitor Service) in two sub-groups with showroom A1, Corp. History A3, Tablet Production Ph80, Toxicology U9		Barbara Hoffmann & Sabine Eiers
11:30 – 12:00 12:00 – 12:20	Activity for Group B Pharmaceutical Development How to build Effective Drug Safety in Africa		Atrium B4 Markus Weigandt Kristina Strutt
12:20 – 12:30	COFFEE BREAK		
12:30 – 12:50 12:50 – 13:30	How to build Effective Supply Chain practices in Africa Q&A about Sessions, followed by Group Networking		Alessandro De Luca
13:30 – 15:30	LUNCH		Guest Restaurant

MERCK AFRICA LUMINARY AGENDA

DAY 1
23rd October 2014 (Thursday)
Atrium B4
15:30 – 17:30
R&D Manufacturing Site Educational Visit

(2 Groups) each Group is 50 Guests – 25 Guests in each sub-groups)
Group B will take the bus for Scientific Tour and **Group A** will stay behind at the Atrium for a parallel activity

15:30 – 17:30
Activity for Group B (Scientific Tour)

Group B (50 Guests) does visit (Visitor Service) in two sub-groups with Showroom A1, Corp. History A3, Tablet Production Ph80, Toxicology U9

**Barbara Hoffmann
 & Sabine Eiers**
**15:30 – 15:50
 15:50 – 16:10**
Activity for Group A

Pharmaceutical Development
 How to build Effective Drug Safety in Africa

**Atrium B4
 Markus Weigandt
 Kristina Strutt**
16:10 – 16:20
COFFEE BREAK
**16:20 – 16:40
 16:40 – 17:30**

How to build Effective Supply Chain practices in Africa
 Q&A about Sessions, followed by Group Networking

Alessandro De Luca
17:30
Going back to the Hotel
19:30 – 22:00
Dinner
L'Orangerie Restuarant
20:00– 20:15
Key Notes and Welcome Message
20:15 – 22:00
DINNER Served

MERCK AFRICA LUMINARY AGENDA

DAY 2

24th October 2014 (Friday)

Atrium B4

09:00 – 09:35 **Priority Health Issues in Africa – Communicable vs. Non-Communicable Diseases**
Dr. Francis Omaswa

09:35 – 10:05 **Communicable Diseases and a Current Crisis**
Dr. Guy Richards

10:05 – 10:25 **Merck Praziquantel Donation Program**
Frank Gotthard

10:25 – 10:40 **R&D in Neglected Tropical Diseases**
Jutta Reinhard – Rupp

10:40 – 10:50 **COFFEE BREAK**

10:50 – 12:35 **Group Sessions**

Group 1 Diabetes Sessions

Atrium B4

10:50 – 11:40 **Assessment of Emerging Therapies for Patients with Type 2 Diabetes Mellitus**
Prof. Ian Campbell

11:40 – 12:35 **Type 2 Diabetes: where Guidelines, Science and Clinical Practice Meet**
Dr. Harry Howlett

12:35 – 12:45 **COFFEE BREAK**

Group 2 Fertility Sessions

Auditorium B10

10:50 – 11:40 **Fertility in Africa – Society Perceptions and Treatment Challenges**
Dr. Vittorio Colizzi

11:40 – 12:35 **Algorithms for Diagnosis and Treatment of Fertility**
Dr. Carlo Alviggi

12:35 – 12:45 **COFFEE BREAK**

Group 3 Oncology Sessions

Room 3 & 5 B10

10:50 – 11:40 **The Growing Trend of Oncological Diseases – Relevance for Africa**
Prof. David Kerr

11:40 – 12:35 **Optimal Treatment Strategy in mCRC**
Prof. Volker Heinemann

12:35 – 12:45 **COFFEE BREAK**

MERCK AFRICA LUMINARY AGENDA

DAY 2

24th October 2014 (Friday)

Atrium B4

12:45 – 13:45

Group Sessions

12:45 – 13:45

Group 1 Diabetes Sessions

Atrium B4

"Merck Capacity Advancement Program" in Diabetes and Hypertension in Africa
Rasha Kelej

12:45 – 13:45

Group 2 Fertility Sessions

Auditorium B10

Individual Protocols for Fertility Treatment
Dr. Robert Fischer

12:45 – 13:45

Group 3 Oncology Sessions

Room 3 & 5 B10

The role of biomarkers in personalising cancer therapeutics
Prof. David Kerr

13:45 – 15:00

LUNCH

Guest Restaurant

15:00 – 15:40

Panel Discussion

Atrium B4

Health Issues and Priorities in Africa Counterfeit Medicines & Good Distribution Practices
"What can we do together"
Dr. Steven Hildemann, Academics, KOL's

15:40 – 15:50

Q&A

15:50 – 16:10

Final Messages of the Program and vote of thanks
Elcin Ergun

16:15

Back to the Hotel

MERCK AFRICA LUMINARY

Together We Commit To Africa




Darmstadt, Germany 23rd, 24th October 14

Objectives:

Contribute to Africa's Social and Economic Development.

- Advance Healthcare Capacities and Capabilities
- Improve Access to High Quality and Innovative Healthcare Solutions.

-
- Provide medical education sessions to improve disease management awareness.
 - Discuss priority health issues in Africa –Communicable vs. Non- Communicable Diseases– policies and strategies to address risk.
 - Contribute to improving patient safety practices.
 - Contribute to improving supply chain integrity, applying GDP and fighting counterfeit medicines.



Elcin Ergun

Executive Vice President,
Head of Global Commercial
Merck Serono

23rd October 2014

08:00 hrs – 08:15 hrs

Elcin Ergun was appointed Executive Vice President, Head of Global Commercial and Member of Pharmaceutical Executive Committee as of January 2, 2014 in Merck Serono.

She was Senior Vice President, Head of Intercontinental Region of Merck Serono comprising of Middle East, Africa, Turkey, Russia & CIS in 2012–2013.

Between 2006–2011, she was the MD of Merck Turkey, with pharma and chemical operations, and between 1998–2006, she was GM of Serono.

She Joined the pharma industry in 1995 during the inauguration of Smithkline Beecham Turkey as the local CFO.

Prior to that, spent several years in various management capacities in Europe and Turkey including Finance, Sales & Marketing and IT with Honeywell in the UK(1 year), Honeywell in Turkey(1 year) and ITT World Directories based in the Netherlands(5 years).

Elcin has a Bachelor of Science degree in Computer Engineering from METU, Ankara and MBA degree from INSEAD. Married, one daughter.



MERCK AFRICA LUMINARY

Together We Commit To Africa



Darmstadt, Germany 23rd, 24th October 14

A Successful History

Merck is the Oldest Pharmaceutical and Chemical Company in the World. Its roots date back to the year 1668.



Dr. Frank Stangenberg-Haverkamp

Chairman of the Executive Board
and Family Board of E. Merck KG
and Member of the Merck family.

23rd October 2014

08:15 hrs – 08:45 hrs

Dr. Frank Stangenberg-Haverkamp, born in 1948 in Dorsten, Germany. He is The Chairman of the Executive Board and Family Board of E. Merck KG and member of the Merck family,

Following his German University entrance qualification (Abitur) he served with the German Air Force, which he left as Lieutenant.

At the University of Freiburg/Br. he studied economics and economic history.

After completing his studies he worked at Commerzbank and the Investment Banks Baring Brothers and Hambros in London.

In 1984 he was elected to the Board of Partners of E. Merck KG and has been the Chairman of the Board since 2004.

In January 2014 he was elected as the Chairman of the Executive Board and the Family Board of E. Merck KG.

Frank Stangenberg-Haverkamp is married and has 7 children.





Dr. Karl-Ludwig Kley
Chairman of the Executive
Board of Merck

23rd October 2014

08:45 hrs – 09:15 hrs

Karl-Ludwig Kley, born on June 11, 1951 in Munich, Germany, has been Chairman of the Executive Board of Merck since April 2007. Prior to this, he was appointed Vice Chairman of the Executive Board in September 2006.

Before joining Merck, Karl-Ludwig Kley was a member of the Executive Board of Deutsche Lufthansa AG from 1998 to 2006. There he served as Chief Financial Officer.

From 1982 to 1998, Karl-Ludwig Kley worked for Bayer AG, most recently as Head of Corporate Finance and Investor Relations. He also served as Head of the Pharmaceutical division at the Italian subsidiary of Bayer from 1994 to 1997, held a number of senior executive positions within sales and marketing of the Pharmaceutical division from 1991 to 1994, and was Chief Financial Officer of Bayer in Japan from 1987 to 1991. At the beginning of his career with Bayer, Karl-Ludwig Kley initially worked in Corporate Finance and later became assistant to the Chairman of the Management Board.

Karl-Ludwig Kley completed an industrial business apprenticeship at Siemens AG and then studied law at Ludwig-Maximilians University of Munich from 1974 to 1979. He completed his practical training as a lawyer in Hamburg and Johannesburg from 1979 to 1982. While working, he earned a doctorate in law (Dr. jur.) from the University of Munich in 1986. He is married and has one son.





Dr. Stefan Oschmann

Member of the Executive Board of Merck
CEO Pharma

23rd October 2014

09:15 hrs – 09:40 hrs

Stefan Oschmann, born on July 25, 1957 in Würzburg, Germany, has been a member of the Executive Board of Merck since January 2011 and is responsible for the Merck Serono and Consumer Health divisions, as well as the business units Allergopharma and Biosimilars.

On January 1st, 2015, Stefan Oschmann will be appointed **Member of the Executive Board of Merck CEO Pharma Vice Chairman and Deputy CEO of Merck.**

Before joining Merck, he worked for the Pharma company MSD (in the US and Canada Merck & Co.). There he served most recently as President of Emerging Markets. His prior positions at MSD included Member of Senior Management and Corporate Officer with responsibility for the business in Europe, the Middle East, Africa and Canada, Senior Vice President in charge of Worldwide Human Health Marketing, as well as Vice President of Europe and the German business. Before that, Stefan Oschmann held various positions in Belgium, the Netherlands, Austria and eastern Europe.

Prior to joining MSD, Stefan Oschmann worked for the International Atomic Energy Agency IAEA from 1985 bis 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989, a member association of the German Chemical Industry Association (VCI).

Stefan Oschmann studied veterinary medicine at Ludwig-Maximilians-Universität in Munich from 1977 to 1982 and earned a doctorate there in 1985. He is married and has two children.





Belén Garijo, MD

President and CEO

Merck Serono

23rd October 2014

09:40 hrs – 10:05 hrs

Belén Garijo, born on July 31, 1960 in Almansa, Spain, has been President and CEO of Merck Serono, the biopharmaceutical division of Merck, since October 2013. She joined Merck Serono as Chief Operating Officer in 2011.

Before joining Merck, Belén Garijo was employed by Sanofi–Aventis as Senior Vice President Global Operations Europe, serving as a member of the Management Committee of the Sanofi–Aventis Group and of the Management Board of the Sanofi–Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi–Aventis in 2004. From 2000 to 2003 she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône–Poulenc Rorer.

Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA.

Belén Garijo is a medical doctor, specialized in clinical pharmacology. She worked as a practicing physician for six years, before moving to the pharmaceutical industry. Belén Garijo is married and has two daughters.

External positions

L'Oréal S.A., Member of the Board of Directors

Banco Bilbao Vizcaya Argentaria S.A., Member of the Board of Directors

PhRMA (Pharmaceutical Research and Manufacturers of America), Member of the Board



MERCK AFRICA LUMINARY

Together We Commit To Africa



Darmstadt, Germany 23rd, 24th October 14

Merck Scientific Tour

The Darmstadt site is the headquarters of the Merck Group. Besides housing production plants for various pharmaceuticals and chemicals

The Darmstadt site is also one of the Global R&D centers, featuring chemical and preclinical research, process development, analytical services, and clinical drug development units



Barbara Hoffmann

Manager Visitor Relations

Site Operations Community Relations

Merck, Darmstadt, Germany

23rd October 2014

11:30 hrs – 13:30 hrs

15:30 hrs – 17:30 hrs

Barbara Hoffmann is Team Leader of Visitor Relations at Merck Darmstadt.

A Graduate Nutrition Scientist by training, she started her career at Merck in 1986. As project manager Barbara was responsible for the conceptualization and coordination of communications projects like image brochures, CD-ROMs and films as well as the conceptualization and organization of big events like Open House Days and "Jugend forscht Landes- und Bundeswettbewerb" (state and federal competition of young scientists).

In 2011 she joined the Visitor Relations team, the experts for individually planning and professionally conducting tours of the Darmstadt headquarters for internal and external visitors from all countries.





Sabine D. U. Eiers

Manager Visitor Relations

Site Operations Community Relations

Merck, Darmstadt, Germany

23rd October 2014

11:30 hrs – 13:30 hrs

15:30 hrs – 17:30 hrs

A Graduate Microbiologist by training, she started her career at Merck in 1986 as key account manager at the pharmaceutical sales force of Merck Germany. After that she was Sales Force Trainer and then Product Manager Heart Diseases.

In 1999 she joined the Visitor Relations team, the experts for individually planning and professionally conducting tours of the Darmstadt headquarters for internal and external visitors from all countries. There she was responsible for image film concepts, quality management concepts and the logistics organization of the Open House Day 2014. She is member of the scientific jury of the "Jugend forscht" state competition of young scientists.





Dr. Markus Weigandt

Senior Director Research Pharmaceuticals
& Drug Product Development
Merck Serono, Darmstadt, Germany

23rd October 2014

11:30 hrs – 12:00 hrs

15:30 hrs – 15:50 hrs

Dr. Weigandt is Head of Research Pharmaceuticals & Drug Product Development at Merck Serono, Darmstadt.

A pharmacist by training, he started his career at Cytonet, a biotech spinoff from Roche.

He joined Merck in 2003 and after positions as Qualified Person and in early pharmaceutical development he is now responsible for a team of ~70 pharmaceutical experts.

He is responsible for the pharmaceutical development, characterization, formulation, process development and GMP manufacturing of Merck-Serono's R&D pipeline in Discovery, clinical development and Life Cycle Management.





Dr. Kristina Strutt

Vice President,
Head of Global Drug Safety
Merck Serono

23rd October 2014

12:00 hrs – 12:20 hrs

15:50 hrs – 16:10 hrs

Tina is a registered physician, having studied medicine at King's College Cambridge and the Middlesex Hospital in London, UK. She is a Member of The Royal College of Physicians and a Fellow of The Faculty of Pharmaceutical Medicine in the UK. She holds specialist registration in pharmaceutical medicine with the UK GMC.

After 5 years' clinical experience with the UK NHS, Tina has now worked for more than 25 years in the pharmaceutical industry. During this time she has worked in lead roles in the clinical development of products in the oncology and cardiovascular therapeutic areas, across all phases of development, including peri-launch market positioning and life-cycle management. In August 2003 Tina moved from Clinical Development into Drug Safety, when she was appointed Director, Global Drug Safety at AstraZeneca. At the beginning of 2011, Tina moved to Merck Serono in Geneva, as Vice President, Head of Global Drug Safety, moving to Darmstadt Germany in 2013.

Tina is passionate about medical education, training and development. She is a lecturer on the Cardiff University MSc/Diploma in Clinical Research Course, for which she also served a four year appointment as external examiner, on the Cardiff University Postgraduate Course in Pharmaceutical Medicine, and on several courses for the Drug Safety Research Unit, University of Portsmouth. She is an examiner for the Faculty of Pharmaceutical Medicine in the UK.





Alessandro De Luca

Senior Vice President Supply Network

Merck Serono

23rd October 2014

12:30 hrs – 12:50 hrs

16:20 hrs – 16:40 hrs

Alessandro joined Merck Serono on November 1st, 2011 as Head of Supply Network Operations within GMS function.

Previously, he has held positions across Innovation& General Management, Procurement, Manufacturing, Logistics, Customer Service and end-to-end Supply Chain Management in FMCG's and Automotive industry.

He has operated in countries such as China, Russia, Venezuela and several Eastern European countries and has been based in Italy, Belgium, Switzerland and Spain.

He completed a degree in Nuclear Engineering in 1991 in Rome as well as a Civil Engineering degree and he holds a Master in Organization Effectiveness.

Alessandro is an Italian citizen, married with one son.



MERCK AFRICA LUMINARY

Together We Commit To Africa



24th October 2014

- Discussion of priority health issues in Africa –Communicable vs. Non-Communicable Diseases– policies and strategies to address risk.
- Medical Education session

Diabetes Session

Fertility Session

Oncology session

MERCK AFRICA LUMINARY

Together We Commit To Africa



Objectives:

Contribute to Africa's Social and Economic Development.

- ▣ Advance Healthcare Capacities and Capabilities
- ▣ Improve Access to High Quality and Innovative Healthcare Solutions.

-
- Provide medical education sessions to improve disease management awareness.
 - Discuss priority health issues in Africa –Communicable vs. Non- Communicable Diseases– policies and strategies to address risk.
 - Contribute to improving patient safety practices.
 - Contribute to improving supply chain integrity, applying GDP and fighting counterfeit medicines.



Dr. Francis Omaswa

Executive Director

African Center for global Health and
Social Transformation (ACHEST)

24th October 2014

09:00 hrs – 09:35 hrs

Dr. Francis Omaswa is the Executive Director of the African Center for Global Health and Social Transformation (ACHEST), a non-profit organization incorporated in Uganda that champions the development of African rooted capacity, ownership and accountability for health outcomes by promoting better leadership, governance and the pursuit of excellence in health and to support Africa to become a stronger player in international health. He is Chancellor of Busitema University in Uganda, Chair of the African Platform for Human Resources for Health and Co-chair of the Global Policy Council on Health Workforce Migration.

He was special adviser to the Director General of WHO and founding Executive Director of the Global Health Workforce Alliance at WHO and Director General of Health Services in the government of Uganda. He has been a leader in the establishment of several African and global Institutions such as the Uganda Heart Institute, the Regional Center for the Quality of Health Care at Makerere University, the College of Surgeons of East, Central and Southern Africa, the Global Stop TB Partnership and the Global Fund to Fight Aids, TB and Malaria. He has a keen interest in access of the poor to quality health services and spent five years in the rural Ngora hospital in Uganda, testing various approaches for this and supports a number of community developmental initiatives. This year he has published books namely: "Handbook for Health Ministers" and "African Health Leaders: making change and claiming the future".

Dr. Omaswa is a graduate of Makerere Medical School, a Fellow of the College of Surgeons of East Central and Southern Africa, Royal College of Surgeons of Edinburgh, New York Academy of Medicine, Institute of Medicine of the USA and has qualifications in corporate governance, health services management and medical education.





Prof. Guy Richards

Academic Head and Professor
Division of Critical Care,
University of the Witwatersrand

24th October 2014

09:35 hrs – 10:05 hrs

Professor Guy Richards is currently Academic Head and Professor of the Division of Critical Care at the University of the Witwatersrand. He is Director of the Dept. of Critical Care at the Charlotte Maxeke Johannesburg Academic Hospital in Johannesburg and he also is a chief Physician in the Department of Medicine and Pulmonology at the University of the Witwatersrand.

He was awarded his medical degree in 1978, specialised in internal Medicine in 1985 and subsequently qualified as a pulmonologist and intensivist. He was awarded his PhD in Medicine in 1992 from the University of Witwatersrand.

He has twice been the Co-Chairman of the South African national Critical Care and Thoracic Society Congress. He has been invited to speak at numerous meetings on pulmonology and intensive care and has given well over 100 invited presentations at national and international congresses. Professor Richards has been awarded best research paper, best presentation and best publication on a number of occasions at congresses of the SA Thoracic Society (SATS) and the SA Critical Care Society of Southern Africa (CCSSA), most recently in 2008. To date, he has authored 11 book chapters and over 100 scientific papers.

In 2013 he was awarded the PV Tobias convocation award for excellence in teaching at the University of the Witwatersrand





Frank Gotthardt
Head of Public Affairs
Merck Serono

24th October 2014

10:05 hrs – 10:25 hrs

Frank Gotthardt, born on November 15, 1970 in Marburg, Germany, has been the Head of Public Affairs, Merck KGaA, Darmstadt Germany since 2010.

He studied Business Administration at Philipps-University, Marburg, Germany as well as Business & Communication at Pierre-Mendès-France-University, Grenoble, France.

In 1994, he earned his Master's Degree in Business Administration and a scholarship recipient from the Konrad-Adenauer-Foundation

He was a Member of Parliament for the State of Hesse and a Deputy Chairman of the CDU Party's parliamentary group.

In 2003 until 2005, he was a Chief of Staff for the CDU Party, Hesse and in 2007 he became a Senior Consultant, Aegis Media, Berlin.

He is also a Chairman of the Global Pharma Health Fund e. V.





Jutta Reinhard-Rupp

Head of the R&D Translational
Innovation Platform for "Global Health"
Merck Serono

24th October 2014

10:25 hrs – 10:40 hrs

Jutta Reinhard-Rupp is the Head of the R&D Translational Innovation Platform for "Global Health" at Merck Serono.

Her focus is the discovery and development of new drugs and health solutions for children suffering from poverty-related diseases such as malaria and schistosomiasis.

She studied Biology in Mainz and Tübingen and received her PhD at the Max-Planck Institute in Tübingen. After her postdoctoral training at Novartis, she was lab head at Evotec Biosystems in Hamburg.

In 1997, she joined Aventis in various assignments in Research and Development.

Since January 2008, she works with Merck Serono in Switzerland with main responsibilities on the implementation of key strategic initiatives in drug discovery and development, including the lead of several "Global Health" programs.

The current flagship program is the development of a new pediatric formulation of Praziquantel to treat young children in schistosomiasis endemic areas



MERCK AFRICA LUMINARY

Together We Commit To Africa



We take on
responsibility:

Together with the
World Health Organization (WHO),
Merck is fighting the worm disease
schistosomiasis in Africa.



Prof. Ian Campbell

Emeritus Professor of Medicine

Medical School, University of St Andrews

24th October 2014 Diabetes Session 10:50 hrs – 11:40 hrs

Prof. Ian Campbell is Emeritus Professor of Medicine at St Andrews University.

He graduated in medicine in 1969 at Edinburgh University. After training in Edinburgh, he was appointed as Consultant Physician with special interests in Diabetes and Endocrinology to Victoria Hospital, Kirkcaldy (1978–2008).

He was appointed to an Honorary Chair in Department of Medicine at St Andrews University and continues his academic work at St Andrews University.

Professor Campbell has published extensively on the subject of diabetes, its complications and management and is author of over 200 research papers and reviews as well as several diabetes textbooks. His publications have an H index of 33, and the career citations are over 5,000.

He has lectured in over 50 countries, principally on diabetic autonomic neuropathy and oral hypoglycaemic agents. He is presently co-editor of British Journal of Diabetes and Vascular Disease.





Dr. Harry Howlett

Consultant Advisor in Diabetes
HHMS Global Diabetes Research
& Education London
United Kingdom

24th October 2014 Diabetes Session 11:40 hrs – 12:35 hrs

Dr. Harry Howlett is currently a Consultant Research Advisor with a specialist interest in diabetes developed over 30 years.

Formerly, he was a senior international medical advisor in the pharmaceutical sector working closely with the principal investigators of UKPDS and DPP.

His clinical research experience covers almost three decades and he has a doctorate in clinical pharmacology from Leicester.

He has lectured widely and been active in medical education meetings at St Andrews from the 1980s onwards collaborating closely with the University in the last 5 years.

He is currently a fellow of the Royal College of Physicians of Edinburgh and a member of the Royal Pharmaceutical Society of Great Britain.

He is co-author of some 40 publications in the fields of cardiovascular disease, diabetes and alcoholism and a co-author of the 2007 scientific handbook entitled Metformin the Gold Standard.

He is an editorial board member of the British Journal of Diabetes and Vascular Disease and currently holds membership of the American Diabetes Association(ADA) and the European Association for the Society of Diabetes (EASD)





Dr. Vittorio Colizzi

Full Professor of Immunology and Pathology
Director UNESCO Chain in Interdisciplinary
Biotechnology,
University of Rome Tor Vergata,

24th October 2014 Fertility Session 10:50 hrs – 11:40 hrs

Dr. Vittorio Colizzi earned his Medical Degree in 1973 with honor from University of Rome "La Sapienza" followed by a Specialist Degree in Infectious Diseases, University of Rome "La Sapienza" in 1976.

In 1978, he earned a Specialist Degree in Public Health & Hygiene, University of Pisa and in 1987 he obtained a Degree of Doctor of Philosophy in Immunology, Brunel University, Uxbridge, England.

Presently, Dr. Colizzi is a full Professor of Immunology, Head of the Laboratory of Immunology & Molecular Pathology, Department of Biology, Faculty of Medical Sciences, University of Rome "Tor Vergata".

He is also the Head of the Italian-Cameroon AID Programme & Scientific Director at the International Research Centre "Chantal Biya", Yaoundé, Cameroon, Central Africa.

And holder of the UNESCO Chair in Interdisciplinary Biotechnology, University of Rome "Tor Vergata".





Dr. Carlo Alviggi

Specialist in Reproductive Medicine

Fertility Unit of the University of Naples
"Federico II"

24th October 2014 Fertility Session 11:40 hrs – 12:35 hrs

Dr. Carlo Alviggi works as Specialist in Reproductive Medicine at the Fertility Unit of the University of Naples "Federico II".

Since 2006, he has been working in the same Unit as Assistant Professor. His current research interests are the role of LH in folliculogenesis, the use of LH-containing drugs in patients undergoing ovarian controlled stimulation for IVF, the pathogenesis of pelvic endometriosis, and the genetics of human reproduction.

Dr. Alviggi has published extensively and has been invited to lecture at over 40 international meetings dealing with reproductive medicine and gynaecological endocrinology.

He has also served as ad-hoc reviewer for international journals of these fields and has participated in several national and international (phase II-III) multi-centric, prospective randomised trials





Prof. David Kerr

Professor of Cancer Medicine,

University of Oxford and

Adjunct Professor of Medicine,

Weill-Cornell College of Medicine, New York

**24th October 2014 Oncology Session 10:50 hrs – 11:40 hrs
12:45 hrs – 13:45 hrs**

Professor David Kerr has made sustained and internationally recognised contribution to cancer care and research in the field of drug development over the past 3 decades.

He has published over 400 papers in high profile journals authored over twenty books including the Oxford Textbook of Oncology, and has been awarded 4 prestigious, international research prizes.

His scientific standing has been recognised by election as Fellow of Academy of Medical Sciences in 2000, President of the European society of Medical Oncology (2009-2011) and Founding Fellow of the European Academy of Cancer Sciences (2010).

He Chaired the Cancer Services Collaborative (1999-2003), working with Don Berwick to deliver the world's largest redesign programme to improve delivery of the NHS' cancer service (he was awarded CBE by HM the Queen in 2002).

Subsequently, he completed the "Kerr Report" (2006), a 20 year plan to reform Scotland's NHS, he has supported two British Prime Ministers (Tony Blair and David Cameron) in a health advisory role and has served on Qatar's Supreme Health Council.

Internationally, he has established INDOX, India's leading cancer trials network and developed the Oxford based charity Afrox (www.afrox.org) to support cancer control in Africa and meet the educational and training needs of her clinicians.





Prof. Volker Heinemann

Director of the CCC-Munich and Director of the CCC^{LMU}

Department of Medical Oncology and Hematology, Klinikum der Universität München – Grosshadern, Germany

24th October 2014 Oncology Session 11:40 hrs – 12:35 hrs

Dr. Volker Heinemann was born on 10th November 1956 in Hilden, Germany.

He attended the Medical school at the Ludwig Maximilian University (LMU) Munich, Germany from 1976 until 1982.

In 1988, he finished his Post-doctoral fellowship (Project Investigator) at the M.D. Anderson Cancer Center, Section of Molecular Pharmacology (Professor W. Plunkett), Department of Clinical Oncology, University of Texas, USA. Training in biochemical and clinical pharmacology

He is currently the Director of the CCC-Munich, Director of the CCCLMU, Ludwig-Maximilian-University of Munich Head of the Oncology Working Group at the Department of Hematology/Oncology (Medical Clinic and Poliklinik III, University of Munich; Director: Prof. W. Hiddemann)

Since 2005, he is the Senior physician of the oncological out-patient clinic at the Medical Clinic III, University of Munich (Director: Prof. W. Hiddemann)

He is a Member of American Society of Clinical Oncology (ASCO), Deutsche Krebsgesellschaft (DKG), Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), Deutsche Gesellschaft für Senologie, Arbeitsgemeinschaft Internistische Onkologie (AIO) Tumorzentrum Munich





Rasha Kelej

Vice President

Head of Global Business Responsibility,
Market Development and Customer Centricity

Merck Serono

24th October 2014 Diabetes Session 12:45 hrs – 13:45 hrs

Rasha Kelej was born in February 1972 in Alexandria, Egypt and has been Vice president and Head of Global Business Responsibility, Market Development and Customer Centricity since May 2014.

In this position she is responsible for the Social Responsibility strategy and action plan that are integrated with business and market development strategies. She elaborated a structured and coherent Social Responsibility agenda that is adding great value to society and scientific communities in Africa and Developing countries such as India and Indonesia.

One of these initiative is " **Merck Capacity Advancement Program- CAP** "

Rasha's most recent role was Global Strategy Realization Director , prior to this she held the position of Commercial Director of Biosimilars and Head of Special project of Intercontinental Region under which she has developed a regional Biosimilars strategy and CSR & A2M strategies that is adding great value to society and scientific communities in Africa.

Rasha Kelej has more than 20 years of experience in the international pharmaceutical Industry. She joined Merck Serono in 1996 and holds a degree in Pharmacy of Alexandria University and an MBA at Robert Gordon University, Scotland on Corporate Social Responsibility (CSR) integration with Business Strategy.



MERCK AFRICA LUMINARY

Together We Commit To Africa



Merck Capacity Advancement Program
CAP Africa



Dr. Robert Fischer

Medical Director
Fertility Centre Hamburg
Hamburg, Germany

24th October 2014 Fertility session 12:45 hrs – 13:45 hrs

Dr. Robert Fischer did his subinternship at Mount Sinai school of medicine N.Y. USA in 1976.

He did his Obstetric and gynaecologic training at the Department of Obstetrics and Gynaecology at the University Hospital of Münster, Germany in 1979–1982. In 1982, Dr. Fischer did a one year of obstetrics and gynaecology at the Queen's Medical Centre, University of Nottingham (King's Mill Hospital Mansfield). And in 1983, pioneered and medical director of the first outpatient IVF-unit in Germany – Hamburg .

Dr. Fischer is a Medical Director of the Fertility Center Hamburg, which is one of the largest and leading private IVF centres in Germany.

In July 1998 the Fertility Center Hamburg was one of the first centres in Germany and worldwide to introduce quality management to be certified according to the ISO 9001 and in 2002 accreditation of the IVF-Lab. (ISO 17025). Numerous publications in national and international scientific journals, book articles as well as lectures on national and international conferences.

He is the founding member of the European Society of Human Reproduction (ESHRE) Member of the scientific committee of EXCEMED (former-SSIF).

His main interest at the moment is the development of Stimulation Protocols and GnRH-Agonist triggering as well as further developing of the quality management systems in IVF centres.





Dr. Steven Hildemann

Chief Medical Officer,
Head of GMA & GDS
Merck Serono

24th October 2014

15:00 hrs – 15:40 hrs

PD. Dr. Steven Hildemann, Senior Vice President, MD, PhD, is a board certified Internist and Cardiologist trained in Germany and the US.

After 10 years of academic medicine, he joined the industry in a country medical director role.

Over the course of 15 years, Steven progressed to roles of increasing responsibility in Medical Affairs, Late Stage Development and Clinical Operations at the local, regional and global level in leading pharmaceutical organizations.

He led major global change initiatives and organization building efforts before joining Merck Serono in January 2014 in his current role as Chief Medical Officer, Head of GMA and GDS.

In 1998, he obtained a Certification in Internal Medicine and Cardiology from LMU – Munich.

His achievements includes German Awards for Excellence in Humanities, French – German Scholarship for Medical Studies, Doctoral thesis with honors ("Magna Cum Laude") and W.E. Upjohn Award 2002 (Pharmacia Award for Excellence and Leadership)



MERCK AFRICA LUMINARY

Together We Commit To Africa



Objectives:

Contribute to Africa's Social and Economic Development.

- Advance Healthcare Capacities and Capabilities
- Improve Access to High Quality and Innovative Healthcare Solutions.

-
- Provide medical education sessions to improve disease management awareness.
 - Discuss priority health issues in Africa –Communicable vs. Non- Communicable Diseases– policies and strategies to address risk.
 - Contribute to improving patient safety practices.
 - Contribute to improving supply chain integrity, applying GDP and fighting counterfeit medicines.



Dear Delegates,

Welcome to the Merck Africa Luminary.

Below you will find a summary of helpful information regarding your participation in the meeting.

AIRPORT TRANSFERS



Arrival Transfer

On arrival at Frankfurt airport, please proceed to the meeting points as indicated in the picture.

You will find there a representative holding the Merck Serono Signboard, who will then escort to the vehicle.

Meeting Point at Terminal 1

Arrival level 1 (after baggage claim)
next to Exit B1 / Restaurant Marche

Meeting Point at Terminal 2

Arrival level 1 (after baggage claim)
between D and E



AFRICA LUMINARY

If you faced any problems to get there or to find your driver please call 0039 320 2890444.



Departure Transfer

Departure pick-up time is noted in the "Departure Note" included in the Welcome Envelope that you will receive upon arrival at the hotel.

If for any reason, your flights have been changed, please approach the Hospitality desk/Hostess in hotel before 23 October 2014.

Emergency contact number for airport transfers: +39 320 2890444

HOTEL INFORMATION



Maritim Konferenzhotel Darmstadt Hotel

Rheinstraße 105, 64295 Darmstadt

Phone no.: +49 6151 8780

<http://www.maritim.com/en/hotels/germany/konferenzhotel-darmstadt/hotel-overview>



Breakfast

Breakfast will be included during your stay and will be served as follows: Landgraf Restaurant (ground floor)
week days between 06.30 and 10.30 – weekends between 07.00 and 11.00



Check-in time

Please note that the official check-in time is at 15:00



Check-out time

The check-out time is 12:00. Your hotel and breakfast charges have been paid in advance.

Kindly settle your extras upon check-out (i.e. laundry, telephone bills, mini bar, etc) within 12:00 of departure date.

USEFUL INFORMATION



Climate forecast

The weather starts to cool down in Germany in October, when the autumn season is setting in. At this time of year, the **average temperature** is 12°C.



Currency

The official currency in Germany is the Euro.



USEFUL INFORMATION



Credit cards

All the main international credit card are accepted in Germany.



Time in Darmstadt

During Summer Time (Daylight Saving Time), Germany Time is GMT+2 (BST) (until the last Sunday in October).



Dialing code

The telephone country code is +49

MEETING VENUE



Merck Head Quarter in Darmstadt

Merck KGaA

Frankfurter Str. 250

Postcode: A003/K02 - 64293

Darmstadt, Germany



DAY BY DAY Agenda

22nd October, 2014

Arrival and transfer to the hotel

20:30 Welcome Dinner at the hotel – Room Saal
Maritim 1 & 2 (ground floor)
Dress code: Casual

23rd October, 2014

Please check your badge!

We kindly ask you to keep in mind the group capital letter (GROUP A or GROUP B) and the colour of your lanyard and on your badge, as it will identify your group during the whole meeting.

- Red —————> Oncology
- Green —————> Fertility
- Blue —————> Diabetes and Cardiologists and others

07:15 Meet-up in the hotel lobby and transfer to the
Merck Head Quarter in Darmstadt

08:00–11:10 Scientific Sessions in the meeting room "Atrium"
(Building B4)

11:10–11:30 Coffee break

11:30–13:30 Group A: Visit

Group B: Scientific Sessions in the meeting room
"Atrium" (Building B4)

13:30–15:30 Lunch at the Restaurant (Building B10)

15:30–17:30 Group B: Visit

Group A: Scientific Sessions in the meeting room
"Atrium" (Building B4)

17:30 Transfer back to the Walk to the Maritim
Konferenzhotel Darmstadt Hotel





DAY BY DAY Agenda

23rd October, 2014

19:00 Meet-up in the hotel lobby and
transfer to the restaurant

19:30 Dinner at the **Orangerie Restaurant**
Bessunger Straße 44, 64285 Darmstadt
Dress code: Smart Casual

After dinner Transfer back to the hotel



DAY BY DAY Agenda

24th October, 2014

08:15 Meet-up in the hotel lobby and transfer to the Merck Head Quarter in Darmstadt

09:00-10:40 Scientific Sessions in the meeting room "Atrium" (Building B4)

10:40 - 10:50 Coffee Break

10:50- 12:35 Group sessions

- Blue group: Scientific Sessions in the meeting room "Atrium" (Building B4)
- Green group: Scientific Sessions in the meeting room "Auditorium" (Building B10)
- Red group: Scientific Sessions in the meeting room "Room 3&5" (Building B10)

12:35-12:45 Coffee Break

12:45- 13:45 Group sessions

- Blue group: Scientific Sessions in the meeting room "Atrium" (Building B4)
- Green group: Scientific Sessions in the meeting room "Auditorium" (Building B10)
- Red group: Scientific Sessions in the meeting room "Room 3&5" (Building B10)

13:45-15:00 Lunch at the Restaurant (Building B10)

15:00-15:40 Panel discussion & Final Messages in the meeting room "Atrium" (Building B4)

15:40 - 15:50 Q&A



DAY BY DAY Agenda

24th October, 2014

15:50 – 16:10 Final massages of the Program and Vote of Thanks

16:10 Transfer back to the Hotel

We wish you a productive and informative meeting as well as a pleasant stay in Darmstadt!

Thank you and best regards,

Leonard Saika
Regional Head of Business Responsibility,
Market Development and Customer
Centricity for Africa

Mrs. Federica Russetti
Senior Project Manager

Merck Serono
Mobile : + 254 722 762 037
Email: leonard.saika@merckgroup.com

Meridiano Congress International
Via Sapri, 6 - 00185 Rome, Italy
Email: leonard.saika@merckgroup.com
Mobile: +39 320 2890444

Russell Febrero
Marketing Associate
Merck Serono
Mobile : +971-55-3917264
Email: russell.febrero@merckgroup.com





MERCK AFRICA LUMINARY

Together We Commit To Africa